TrialCancer research and treatment2020

Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.

Seok Jin Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.